Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- AAOI +18.4%, ( raises Q3 guidance ), FRAN +13.7%, WDC +6.2%, MBUU +4.7%, HQY +4.1%,
- BZH +2.9%, (announces preliminary results for the first two months of its fiscal Q4), AGX +2.3%, SCWX +1%
Other news:
- RTRX +25.9% (announces positive top-line results from the Phase 2 DUET study of sparsentan)
- CRIS +19.3% (announces its collaborator, Aurigene Discovery Technologies, will receive 10.2 million shares of its common stock at $2.40/share)
- AGIO +13.3% (nnounced that its collaboration partner Celgene (CELG) expects to submit a new drug application for enasidenib)
- XTLB +13.2% ( announces the European Patent Office has granted a patent for lupus drug candidate hCDR1)
- GVP +11.7% (receives contracts to provide updates to nuclear site simulator platforms for customers in the UK and Japan; two projects add over $6 mln to its backlog and include options that could grow backlog significantly further)
- CLCD +9.7% (after 100%+ move higher on Tuesday)
- PGNX +7% (Valeant Pharma and Progenics announce the U.S. commercial launch Of FDA-approved Relistor Tablets; poster presentations to highlight RELISTOR tablets during PAINWeek in Las Vegas, on September 6-10)
- BLRX +6.7% (enters a collaboration w/ Roche Group)
- RPTP +6% (presents data from Meta-Analysis demonstrating efficacy of QUINSAIR)
- CMG +5.7% ( Pershing Square discloses 9.9% active stake, intends to engage in discussions with management and the Board)
- STX +3.4% (in sympathy with WDC)
- VRX +2.3% (Valeant Pharma and Progenics announce the U.S. commercial launch Of FDA-approved Relistor Tablets; poster presentations to highlight RELISTOR tablets during PAINWeek in Las Vegas, on September 6-10)
- CS +1.6% (announced that Tim O'Hara will be succeeded by Brian Chin, currently Co-Head of Credit, as CEO of Global Marketsg)
- MYL +1.4% (modestly rebounding following yesterday's weakness)
Analyst comments:
- AV +1.3% (upgraded to Buy at UBS)
- SGEN +0.7% (initiated with a Overweight at Morgan Stanley)
- COP +0.6% (upgraded to Hold at Jefferies)